|
Nettes Kursziel Axsome Therapeutics (AXSM) PT Raised to $31 at Ladenburg Thalmann https://www.streetinsider.com/Analyst+Comments/Axsome+Therap… Ladenburg Thalmann raised its price target on Axsome Therapeutics (NASDAQ: AXSM) to $31.00 (from $28.00) while maintaining a Buy rating. Analyst Matt Kaplan comments "Interim Phase 3 data for CRPS is expected in 4Q17, with AXS-02 potentially being initially launched in the US in 2019, and other indications following in later years. We estimate AXS-02 can achieve $150 million in revenue in CRPS, with other pain indications also adding materially. At peak, we estimate AXS-02 can reach $600 million." |
|
| aus der Diskussion: | AXSM (Mkap $83 M) (Cash $40 M) 4 x Phase 3 Studien /erste Daten im 2H 2017 |
| Autor (Datum des Eintrages): | Biohero (26.07.17 14:06:04) |
| Beitrag: | 117 von 268 (ID:55395926) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |